CITATIONS:
  1. Bhagirath A, Li Y, Somayajula D, Dadashi M, Badr S, Duan K. Cystic fibrosis lung environment and Pseudomonas aeruginosa infection. BMC pulmonary medicine . 5 Dec. 2016;16(1): 174.
  2. Kerem E, Viviani L, Zolin A, MacNeill S, Hatziagorou E, Ellemunter H, Drevinek P, Gulmans V, Krivec U, Olesen H, ECFS Patient Registry Steering Group. Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS Patient Registry. European Respiratory Journal . 2014 Jan;43(1):125-33.
  3. Flume PA, Mogayzel PJ, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC, Clinical Practice Guidelines for Pulmonary Therapies Committee. Cystic Fibrosis Pulmonary Guidelines: Treatment of Pulmonary Exacerbations. Am J Respir Crit Care Med . 2009 Nov 1;180(9):802-8.
  4. Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet . 1995 Feb;28(2):143-60.
  5. Kelvin H, Tan V, Mulheran M, Knox AJ, Smyth AR. Aminoglycoside Prescribing and Surveillance in Cystic Fibrosis. Am J Respir Crit Care Med. 2003;167: 819–823.
  6. Bates RD, Nahata MC, Jones JW, Mccoy K, Young G, Cox S, Barson W. Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis. Chest . 1997;112 (5): 1208– 1213.
  7. Coulthard KP, Peckham DG, Conway SP, Smith CA, Bell J, Turnidge J. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis—caution with trough concentrations. J Cyst Fibros . 2007 Apr;6(2):125-30.
  8. Barclay ML, Kirkpatrick CM, Begg EJ. Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored? Clin Pharmacokinet . 1999 Feb;36(2):89-98.
  9. ZEMDRI® (plazomicin) injection package insert. Achaogen Inc. Revised 1/2020.
  10. Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity.Antimicrob Agents Chemother . 1999 Jul;43(7):1549-55.
  11. Prescott WA, Nagel JL. Extended-Interval Once-Daily Dosing of Aminoglycosides in Adult and Pediatric Patients with Cystic Fibrosis.Pharmacotherapy 2010;30(1):95–108.
  12. Khwaja A: Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Acute Kidney Injury. Nephron Clin Pract.2012;120:179-184.
  13. VandenBussche HL, Homnick DN. Evaluation of Serum Concentrations Achieved with an Empiric Once-Daily Tobramycin Dosage Regimen in Children and Adults With Cystic Fibrosis. J Pediatr Pharmacol Ther. 2012 Jan;17(1):67-77.
  14. Young DC, Zobell JT, Stockmann C, Waters CD, Ampofo K, Sherwin C, Spigarelli MG. Optimization of Anti-Pseudomonal Antibiotics for Cystic Fibrosis Pulmonary Exacerbations: V. Aminoglycosides. Pediatric Pulmonology. 2013 Nov;48(11):1047-61.
  15. Zobell JT, Epps K, Kittell F, Sema C, McDade EJ, Peters SJ, Duval MA, Pettit RS. Tobramycin and Beta-Lactam Antibiotic Use in Cystic Fibrosis Exacerbations: A Pharmacist Approach. J Pediatr Pharmacol Ther. 2016;21(3):239–246.
  16. Smyth AR, Bhatt J, Nevitt SJ. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database of Systematic Reviews 2017 (3).
  17. Master V, Roberts GW, Coulthard KP, Baghurst PA, Martin A, Roberts ME, Onishko CR, Martin AJ, Linke RJ, Holmes M, Jarvinen A, Kennedy D, Colebatch KA, Hansman D, Parsons DW. Efficacy of once-daily tobramycin monotherapy in acute pulmonary exacerbation of cystic fibrosis. Pediatr Pulmonol. 2001 May;31(5):367-76.
  18. Whitehead A, Conway SP, Etherington C, Caldwell NA, Setchfield N, Bogle S. Once-daily tobramycin in the treatment of adult patients with cystic fibrosis. Eur Respir J. 2002;19:303–309.
  19. Smyth A, Tan KH, Hyman-Taylor P, Mulheran M, Lewis S, Stableforth D, Prof Knox A; TOPIC Study Group. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis–the TOPIC study: a randomised controlled trial.Lancet . 2005 Feb 12-18;365(9459):573-8.